Do you know if the patients that relapsed in the GT2/GT3 monotherapy study were confirmed to have the wild-type virus?
No I don't but I assume GILD/VRUS are aware of the importance of looking for resistant variants in relapsers after DAA therapy and thus perform genotypic sequence analysis at the begging of therapy, at the end of treatment, and during short-term and long-term follow-up evaluation.
Market Data 
Markets 
AI
